PriceTargets.com logo

Sol-Gel Technologies - SLGL Stock Price Target and Predictions

  • Consensus Rating: Strong Buy
  • Consensus Price Target: $8.00
  • Forecasted Upside: 761.51%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 1 Strong Buy Ratings
$0.93 As of 04/19/2024 01:00 AM ET
▲ +0.03 (3.34%)

This chart shows the closing price for SLGL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sol-Gel Technologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SLGL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SLGL

Analyst Price Target is $8.00
▲ +761.51% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Sol-Gel Technologies in the last 3 months. The average price target is $8.00, with a high forecast of $9.00 and a low forecast of $7.00. The average price target represents a 761.51% upside from the last price of $0.93.

This chart shows the closing price for SLGL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Strong Buy

The current consensus among 2 polled investment analysts is to buy (strong buy) stock in Sol-Gel Technologies. This Strong Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/13/2023HC WainwrightLower TargetBuy ➝ Buy$12.00 ➝ $9.00Low
8/14/2023HC WainwrightLower TargetBuy ➝ Buy$19.00 ➝ $12.00Low
8/11/2023Raymond JamesLower TargetStrong-Buy ➝ Strong-Buy$9.00 ➝ $7.00Low
7/24/2023HC WainwrightReiterated RatingBuy ➝ Buy$19.00Low
7/19/2023Raymond JamesLower Target$10.00 ➝ $9.00Low
4/12/2023HC WainwrightReiterated RatingBuy$19.00Low
3/14/2023Raymond JamesLower TargetStrong-Buy$13.00 ➝ $10.00Low
2/1/2023HC WainwrightReiterated RatingBuy$19.00Low
11/14/2022HC WainwrightLower TargetBuy$22.00 ➝ $19.00Low
11/11/2022Raymond JamesLower TargetStrong-Buy$16.00 ➝ $13.00Low
10/21/2022Jefferies Financial GroupInitiated CoverageHold$5.50Low
8/29/2022HC WainwrightBoost TargetBuy$21.00 ➝ $22.00Low
4/25/2022HC WainwrightBoost TargetBuy$20.00 ➝ $21.00High
4/18/2022HC WainwrightReiterated RatingBuy$20.00High
4/1/2022Raymond JamesLower TargetStrong-Buy$21.00 ➝ $17.00Medium
12/23/2021HC WainwrightReiterated RatingBuy$20.00Low
11/15/2021HC WainwrightLower TargetBuy$21.00 ➝ $19.00Low
11/12/2021Raymond JamesLower TargetStrong-Buy$23.00 ➝ $21.00Medium
8/25/2021BMO Capital MarketsReiterated RatingBuy$17.00Low
8/9/2021HC WainwrightReiterated RatingBuy$21.00Medium
7/28/2021HC WainwrightBoost TargetBuy$20.00 ➝ $21.00High
7/12/2021HC WainwrightReiterated RatingBuy$21.00 ➝ $20.00Low
6/29/2021BMO Capital MarketsLower TargetOutperform$20.00 ➝ $17.00High
9/1/2020Raymond JamesReiterated RatingBuyHigh
6/30/2020HC WainwrightReiterated RatingBuy$21.00Low
5/18/2020HC WainwrightReiterated RatingBuy$21.00High
3/26/2020HC WainwrightLower TargetBuy$26.00 ➝ $21.00Medium
12/31/2019Jefferies Financial GroupBoost TargetBuy$14.00 ➝ $24.00High
12/31/2019HC WainwrightBoost TargetBuy ➝ Buy$23.00 ➝ $26.00High
12/31/2019JMP SecuritiesBoost TargetOutperform$20.00 ➝ $33.00High
12/30/2019Raymond JamesBoost TargetStrong-Buy$21.00 ➝ $23.00N/A
12/11/2019HC WainwrightReiterated RatingBuy$23.00Low
12/2/2019HC WainwrightReiterated RatingBuy$23.00Medium
7/9/2019HC WainwrightBoost TargetBuy$21.00 ➝ $23.00High
6/24/2019HC WainwrightReiterated RatingBuy$21.00High
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.33 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Sol-Gel Technologies logo
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; SGT-610, a rare disease for the treatment of Gorlin Syndrome which has completed Phase II clinical trials; and Erlotinib and Tapinarof to treat other rare skin indications. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Read More

Today's Range

Now: $0.93
Low: $0.89
High: $1.00

50 Day Range

MA: $1.03
Low: $0.82
High: $1.30

52 Week Range

Now: $0.93
Low: $0.79
High: $4.05

Volume

11,957 shs

Average Volume

29,011 shs

Market Capitalization

$25.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.33

Frequently Asked Questions

What sell-side analysts currently cover shares of Sol-Gel Technologies?

The following equities research analysts have issued stock ratings on Sol-Gel Technologies in the last twelve months: HC Wainwright, and Raymond James.
View the latest analyst ratings for SLGL.

What is the current price target for Sol-Gel Technologies?

2 Wall Street analysts have set twelve-month price targets for Sol-Gel Technologies in the last year. Their average twelve-month price target is $8.00, suggesting a possible upside of 761.5%. HC Wainwright has the highest price target set, predicting SLGL will reach $9.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $7.00 for Sol-Gel Technologies in the next year.
View the latest price targets for SLGL.

What is the current consensus analyst rating for Sol-Gel Technologies?

Sol-Gel Technologies currently has 1 buy rating and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Strong Buy."
View the latest ratings for SLGL.

What other companies compete with Sol-Gel Technologies?

Other companies that are similar to Sol-Gel Technologies include Eyenovia, Acurx Pharmaceuticals, Aileron Therapeutics, Forte Biosciences and Enlivex Therapeutics. Learn More about companies similar to Sol-Gel Technologies.

How do I contact Sol-Gel Technologies' investor relations team?

Sol-Gel Technologies' physical mailing address is 7 GOLDA MEIR ST. WEIZMANN SCIENCE PARK, NESS ZIONA L3, 7403648. The company's listed phone number is (728) 931-3433 and its investor relations email address is [email protected]. The official website for Sol-Gel Technologies is www.sol-gel.com. Learn More about contacing Sol-Gel Technologies investor relations.